Your browser doesn't support javascript.
loading
Pharmacologic Treatment of Portal Hypertension.
Wong, Yu Jun; Abraldes, Juan G.
Affiliation
  • Wong YJ; Liver Unit, Division of Gastroenterology, University of Alberta, Edmonton, Canada; Liver Unit, Division of Gastroenterology, University of Alberta, 1-38 Zeidler Ledcor Centre, 8540 112 Street Northwest, Edmonton, Alberta T6G 2X8, Canada.
  • Abraldes JG; Liver Unit, Division of Gastroenterology, University of Alberta, 1-38 Zeidler Ledcor Centre, 8540 112 Street Northwest, Edmonton, Alberta T6G 2X8, Canada. Electronic address: juan.g.abraldes@ualberta.ca.
Clin Liver Dis ; 28(3): 417-435, 2024 Aug.
Article in En | MEDLINE | ID: mdl-38945635
ABSTRACT
Portal hypertension is the key mechanism driving the transition from compensated to decompensated cirrhosis. In this review, the authors described the pathophysiology of portal hypertension in cirrhosis and the rationale of pharmacologic treatment of portal hypertension. We discussed both etiologic and nonetiologic treatment of portal hypertension and the specific clinical scenarios how nonselective beta-blocker can be used in patients with cirrhosis. Finally, the authors summarized the evidence for emerging alternatives for portal hypertension in patients with cirrhosis.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adrenergic beta-Antagonists / Hypertension, Portal / Liver Cirrhosis Limits: Humans Language: En Journal: Clin Liver Dis Journal subject: GASTROENTEROLOGIA Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adrenergic beta-Antagonists / Hypertension, Portal / Liver Cirrhosis Limits: Humans Language: En Journal: Clin Liver Dis Journal subject: GASTROENTEROLOGIA Year: 2024 Document type: Article Affiliation country: